Gemin X Biotechnologies
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
400 Chesterfield Pkwy Ste 100, Malvern, ...Phone Number
(610) 640-5735Website
www.geminx.comRevenue
$6.7 MillionIndustry
About Gemin X Biotechnologies
Gemin X Biotechnologies Org Chart
Is Gemin X Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Gemin X Biotechnologies
Website visits: Recent activity has been detected on your website
Check if Gemin X Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Gemin X Biotechnologies recently announced quarterly report
Funding: Get notified immidiatlly once Gemin X Biotechnologies has new funding data
Check out if Gemin X Biotechnologies is spiking on competitors!
Product Launch: Get notified when Gemin X Biotechnologies launches new products
Click to see if Gemin X Biotechnologies had a recent Job posting/layoffs
Gemin X Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Gemin X Biotechnologies as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Gemin X Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Gemin X Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Gemin X Biotechnologies.
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gemin X Biotechnologies
Gemin X Pharmaceuticals specializes in the discovery and development of novel target-based cancer therapeutics. Gemin X's lead product, obatoclax (GX15-070), a small molecule, pan Bcl-2 inhibitor, is currently in Phase 2 clinical trials in both hematological and solid tumor cancers. Gemin X's second compound GMX1777, is a potent, small molecule tha... Read More